Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a staged hybrid ablation procedure compared to the standard catheter ablation in patients with non-paroxysmal atrial fibrillation AF and heart failure. This randomized controlled trial aims to determine which approach better prevents persistent atrial arrhythmia over a follow-up period extending to 24 months after treatment. Participants will be randomly assigned to one of two treatment groups. One group will undergo a staged convergent hybrid ablation, consisting of a minimally invasive surgical epicardial ablation with optional left atrial appendage exclusion followed by an endocardial catheter ablation. The other group will receive the standard percutaneous endocardial catheter ablation alone. The trial compares these two device-based procedures to assess their impact on heart rhythm and heart function. During the study, participants will be closely monitored for heart rhythm changes, heart chamber remodeling, and quality of life using various assessments before treatment and at 12 and 24 months afterward. The main outcome measured is freedom from persistent atrial arrhythmia after a single procedure without certain medications. Safety is also tracked within 30 days and beyond. Overall, the trial will last at least two years for each participant, including follow-up evaluations at multiple time points.
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.
Actively Recruiting
Researchers are evaluating Izalontamab Brengitecan BMS-986507 compared with platinum-based chemotherapy combined with pemetrexed for patients with EGFR-mutated non-small cell lung cancer that has progressed despite prior EGFR tyrosine kinase inhibitor TKI therapy. This study is a randomized, open-label phase 23 trial sponsored by Bristol-Myers Squibb, aiming to determine effective treatment options after failure of EGFR TKI therapy. Participants receive one of several regimens including Izalontamab Brengitecan or platinum-based chemotherapy with pemetrexed, using drugs such as carboplatin, cisplatin, and pemetrexed administered at specified doses on specified days. The study uses a parallel design with randomized assignment to different treatment arms to compare outcomes. Throughout the study, participants will be monitored for progression-free survival and response to treatment using RECIST v1.1 criteria through blinded independent central review, with assessments continuing for up to three years. The recommended phase 3 dose of Izalontamab Brengitecan will be determined about three months after the first dose. Overall survival and multiple secondary outcomes will also be tracked, with the study lasting until November 2030.
Actively Recruiting
Researchers are evaluating a new blood test called Avantect to see if it can detect pancreatic cancer early in people aged 50 to 84 who have recently been diagnosed with type 2 diabetes or have elevated blood sugar levels. Pancreatic cancer is very deadly because it is often found too late for surgery, so early detection could improve treatment options. This trial aims to find out if Avantect can identify pancreatic cancer signals before symptoms appear. Participants will have their blood tested using the Avantect device at three scheduled visits over one year. If the test detects pancreatic cancer markers, participants and their doctors will be informed to arrange further imaging scans like MRI or CT to confirm the diagnosis. The study will track participants remotely for three years after consent to monitor any pancreatic cancer diagnosis or mortality through health registries. During the study, participants will provide blood samples and complete anxiety questionnaires at each visit. Researchers will assess the tests accuracy by measuring its sensitivity and specificity after three years. They will also evaluate how well the test predicts cancer presence, the stage of detected cancers, and surgery rates. The study offers free diagnostic testing and includes ongoing safety and health monitoring for all participants.
Actively Recruiting
Researchers are conducting a post-marketing surveillance study to observe the safety and performance of the SMS femoral stem prosthesis. This observational study involves patients with severely painful or disabling hip conditions such as osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, avascular necrosis of the femoral head, and rheumatoid polyarthritis. The study is sponsored by Medacta International SA and aims to monitor long-term outcomes after primary total hip replacement surgeries. Participants will receive the SMS femoral stem implant as part of their routine primary total hip replacement surgery. The study will observe these patients over a 10-year period to evaluate various outcomes including the survivorship of the implant, clinical and radiographic performance, patient satisfaction, quality of life, patterns of bone remodeling, stem migration, and adverse events. Assessments are scheduled at multiple time points such as 6 weeks, 6 months, 1 year, and annually up to 10 years. During the study, participants will be monitored through clinical evaluations, radiographic imaging, and questionnaires to assess satisfaction and quality of life. The study will track the implants performance and any adverse events over the extended follow-up period. This long-term monitoring aims to provide comprehensive data on how well the SMS femoral stem prosthesis functions and its impact on patients hip health and mobility.